Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $31.81.

A number of equities research analysts have recently commented on NRIX shares. Morgan Stanley lifted their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Finally, HC Wainwright lifted their price target on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE lifted its position in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after purchasing an additional 842 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth $28,000. Amalgamated Bank lifted its position in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares in the last quarter.

Nurix Therapeutics Trading Down 1.5 %

NASDAQ:NRIX opened at $14.05 on Friday. The firm has a 50-day moving average price of $18.18 and a two-hundred day moving average price of $21.62. Nurix Therapeutics has a twelve month low of $11.90 and a twelve month high of $29.56. The company has a market capitalization of $1.07 billion, a P/E ratio of -4.86 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, equities research analysts predict that Nurix Therapeutics will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.